Revvity Signals Banner Ad (Nov-Dec)

EDITORIAL SECTION

KNOWLEDGE BANK

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

  • 4

    Forgotten Biology: The Missing Link Behind Trial Outcomes

    Dr. Sachin Dighe

    Mr. Jayesh Chaudhary

    Trial failure is not always a product failure; often, it is a population-design failure. This article explores how overlooked biological heterogeneity weakens signals, obscures efficacy and undermines...

press releasesRead more...

Sino Biological Introduces AI-Trusted and Qualified Target Protein Collections for AI-Driven Discovery

As AI accelerates recombinant protein and antibody discovery for therapeutic and diagnostic development access to wellcharacterized target proteins is essential for evaluating AIdesigned molecules Sino Biological Inc Shenzhen Stock Exchange SZ a global biotechnology company

Guardant Health Launches Guardant Reveal® Ultra to Deliver Leading Sensitivity in MRD Testing

Guardant Health Inc Nasdaq GH a leading precision oncology company today announced the US clinical launch of Guardant Reveal Ultra a new molecular residual disease MRD platform for solid tumors offering personalized ultrasensitive

Sonic Incytes Announces Multi-Year Partnership with Madrigal Pharmaceuticals to Advance Non-Invasive Liver Assessment in MASH

Sonic Incytes Medical Corp developer of the Velacur pointofcare liver assessment platform today announced a multiyear partnership with Madrigal Pharmaceuticals Inc Nasdaq MDGL a biopharmaceutical company focused on delivering novel

Livsayis™ (cemdisiran) Approved by the FDA as First and Only siRNA Therapy in Generalized Myasthenia Gravis and Only Treatment with Four-Times-a-Year Subcutaneous Dosing

Regeneron Pharmaceuticals Inc NASDAQ REGN today announced that the US Food and Drug Administration FDA has approved Livsayis cemdisiran for the treatment of generalized myasthenia gravis gMG in adult patients

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

24 - 25

Nov 2026

BioPharma Deals Conference 2026

Science Congress Center, Munic...

26 - 28

Nov 2026

One Health Conference 2026

Thapar Institute of Engineerin...

01 - 03

Dec 2026

Pharmaceutical Launch Excellence Summit

Novotel Amsterdam City, Nether...

01 - 03

Dec 2026

10th Antifibrotic Drug Development

Boston, MA at the Hotel Common...

02 - 04

Dec 2026

Genome Informatics 2026

Wellcome Genome Campus, UK

03 - 04

Dec 2026

03 - 04

Dec 2026

LATEST NEWSRead more...

Regeneron Secures FDA Approval for Livsayis, the Seventh Approved Therapy from Alnylam's RNAi Platform

Regeneron has received approval from the US Food and Drug Administration FDA for Livsayis cemdisiran an RNA interference RNAi therapeutic for adults with generalised myasthenia gravis gMG The approval marks the seventh FDAapproved medicine originating from Alnylam Pharmaceuticals RNAi platform in le...

Nanoscope Therapeutics Partners with Uniphar to Expand Access to MOGENRY Across the GCC Region

Nanoscope Therapeutics has entered into an agreement with Uniphar to expand access to its investigational retinal gene therapy MOGENRY sonpiretigene isteparvovec MCO across the six member states of the Gulf Cooperation Council

Scientist.com Launches AI-Ready Market Intelligence Platform for Biopharma R&D

Scientistcom has launched Pharma Observatory a market intelligence platform designed to help biopharmaceutical research and development RD teams understand the competitive landscape surrounding their programmes The platform provides insights into competing research programmes potential business part...

Erasca Partners with Bristol Myers Squibb to Evaluate ERAS-0015 Combination Therapy for Pancreatic Cancer

Clinicalstage precision oncology company Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb BMS to evaluate its investigational drug ERAS in combination with navlimetostat BMS an investigational PRMT inhibitor developed by BMS

GATC Health and Hesperos Join Forces to Develop AI and Human-on-a-Chip Workflow for Preclinical Testing

GATC Health Corp and Hesperos Inc have entered into a strategic collaboration to develop an integrated New Approach Methodologies NAMs workflow aimed at reducing the time and cost of preclinical drug testing before human clinical trials

Novartis’ Cosentyx becomes first anti-IL-17 biologic approved for polymyalgia rheumatica

Novartis has received approval from the US Food and Drug Administration FDA for Cosentyx secukinumab mg to treat adults with polymyalgia rheumatica PMR who have not responded adequately to corticosteroids or cannot tolerate a reduction in their corticosteroid dose